3-Amino-1,2,4-benzotriazine 4-Oxide: Characterization of a New Metabolite Arising from Bioreductive Processing of the Antitumor Agent 3-Amino-1,2,4-benzotriazine 1,4-Dioxide (Tirapazamine)
摘要:
Tirapazamine (1) is a promising antitumor agent that selectively causes DNA damage in hypoxic tumor cells, following one-electron bioreductive activation. Surprisingly, after more than 10 years of study, the products arising from bioreductive metabolism of tirapazamine have not, been completely characterized. The two:previously characterized metabolites are 3-amino-1,2,4-benzotriazine 1-oxide (3) and 3-amino-1,2,4-benzotriazine (5). In this work, 3-amino-1,2,4-benzotriazine 4-oxide (4) is identified for the first time as a product resulting from:one-electron activation of the antitumor agent tirapazamine by the enzymes xanthine/xanthine oxidase and NADPH:cytochrome P450 oxidoreductase. As part of this work, the novel N-oxide (4) was unambiguously synthesized and characterized using NMR spectroscopy, UV-vis spectroscopy, LC/MS, and X-ray crystallography. Under conditions where the parent drug tirapazamine is enzymatically activated, the metabolite 4 is produced but readily undergoes further]reduction to the benzotriazine (5). Thus, under circumstances where extensive reductive metabolism occurs, the yield of the 4-oxide: (4) decreases. In contrast, the isomeric two-electron; reduction product 3-amino-1,2,4-benzotriazine 1-oxide (3) does not readily undergo enzymatic reduction and, therefore, is found as a major bioreductive metabolite under all conditions. Finally, the ability of the 4-oxide metabolite (4) to participate in tirapazamine-mediated; DNA damage is considered.
Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
申请人:Auckland Uniservices Limited
公开号:EP1468688A2
公开(公告)日:2004-10-20
The present invention relates to a synergetistic composition comprising one or more benzoazine-mono-N-oxides, and one or more benzoazine 1,4 dioxides for use in cancer therapy.
The invention also provides a range of novel 1,2,4 benzoazine-mono-N-oxides and related analogues. These can be used as potentiators of the cytotoxicity of existing anticancer drugs and therapies for cancer treatment.
Complete1H,13C and15N NMR assignment of tirapazamine and related 1,2,4-benzotriazineN-oxides
作者:Maruta Boyd、Michael P. Hay、Peter D. W. Boyd
DOI:10.1002/mrc.1886
日期:2006.10
1H, 13C and 15N NMR measurements (1D and 2D including 1H15N gs‐HMBC) have been carried out on 3‐amino‐1, 2,4‐benzotriazine and a series of N‐oxides and complete assignments established. N‐Oxidation at any position resulted in large upfield shifts of the corresponding N‐1 and N‐2 resonances and downfield shifts for N‐4 with the exception of the 3‐amino‐1,2,4‐benzotriazine 1‐oxide in which a small upfield
Urea derivative useful as an anti-cancer agent and process for preparing same
申请人:Chaconne Nsi Co., Ltd.
公开号:US20020019389A1
公开(公告)日:2002-02-14
The present invention relates to a novel urea derivative represented by the following formula (I), which is useful as an anti-cancer agent:
1
its pharmaceutically acceptable acid addition salt or stereoisomer, in which X, Y, B and Het have the meaning as defined in the specification, and to a process for preparing the compound of formula (I) and an anti-cancer composition comprising the compound of formula (I) as an active ingredient.
Synthesis, crystal structure and calculation of oxides of 2-methylamino-3-methyl quinoxaline
作者:Rui Wang、Min Zhang、Wenfeng Wang、Xucheng Wang、Yaofeng Yuan、Junjian Li
DOI:10.1016/j.molstruc.2020.128826
日期:2020.12
Abstract Monoxide and dioxide of animo quinoxaline were synthesized and characterized by 1H NMR, 13C NMR and HRMS. The result shows that monoxide is main product. 1H NMR analysis, quantum calculation and crystalstructure all indicate that the monoxide is 4-oxide structure but not 1-oxide structure. The subsequent discussions of electronic effect and steric effect of 1-oxide and 4-oxide support the